Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Operating Leases: 2019-2024

Historic Operating Leases for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to $90.8 million.

  • Allogene Therapeutics' Operating Leases fell 7.98% to $85.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.1 million, marking a year-over-year decrease of 7.98%. This contributed to the annual value of $90.8 million for FY2024, which is 4.59% down from last year.
  • Allogene Therapeutics' Operating Leases amounted to $90.8 million in FY2024, which was down 4.59% from $95.1 million recorded in FY2023.
  • Over the past 5 years, Allogene Therapeutics' Operating Leases peaked at $101.1 million during FY2022, and registered a low of $53.8 million during FY2020.
  • Its 3-year average for Operating Leases is $95.7 million, with a median of $95.1 million in 2023.
  • Per our database at Business Quant, Allogene Therapeutics' Operating Leases surged by 38.28% in 2022 and then declined by 5.94% in 2023.
  • Over the past 5 years, Allogene Therapeutics' Operating Leases (Yearly) stood at $53.8 million in 2020, then skyrocketed by 35.97% to $73.1 million in 2021, then spiked by 38.28% to $101.1 million in 2022, then dropped by 5.94% to $95.1 million in 2023, then decreased by 4.59% to $90.8 million in 2024.